Across TCGA pan-cancer cohorts, MIR548I2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MIR548I2 data layer compared with 9 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MIR548I2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MIR548I2 expression acts as an unfavorable survival marker.

LUAD, KICH, and LGG are the cancer types where MIR548I2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.263	0.815	<.001	36	view →
KICH	DFS	Median	All	0.102	0.848	.004	13	view →
LGG	OS	Median	All	0.194	0.830	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: MIR548I2 tumor-vs-normal RNA expression · all MIR548I2 data types